Fluticasone

Active ingredient description

Fluticasone has anti-inflammatory and vasoconstrictive features. Fluticasone given by inhalation at recommended doses has a potent glucocorticoid anti-inflammatory action within the lungs, resulting in a reduction of both symptoms and exacerbations of asthma, with a lower incidence and severity of adverse effects than those observed when corticosteroids are administered systemically.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
Fluticasone
D Dermatologicals → D07 Corticosteroids, dermatological preparations → D07A Corticosteroids, plain → D07AC Corticosteroids, potent (group III)
Discover more medicines within D07AC17
Fluticasone
R Respiratory system → R01 Nasal preparations → R01A Decongestants and other nasal preparations for topical use → R01AD Corticosteroids
Discover more medicines within R01AD08
Fluticasone
R Respiratory system → R03 Drugs for obstructive airway diseases → R03B Other drugs for obstructive airway diseases, inhalants → R03BA Glucocorticoids
Discover more medicines within R03BA05

Medicines

Fluticasone is the active ingredient of these drugs:

Drug
Countries

Hong Kong

United States

Ireland

Australia

United States

Netherlands

Cyprus Ecuador Estonia Hong Kong Lithuania

Hong Kong

Hong Kong

Tunisia

Poland

Ecuador

France

Italy

Poland

Austria Brazil Cyprus Ecuador Estonia

Australia Austria Brazil Cyprus Ecuador

France

New Zealand

Ecuador Lithuania South Africa

South Africa

Canada Poland South Africa Spain

Canada United States

Ecuador

Ecuador

Tunisia

Ecuador

Spain

Finland

Poland

Spain

Hong Kong

Italy

Brazil

Cyprus Tunisia

Brazil

Italy Spain

Germany

Germany

Cyprus

Tunisia

Brazil Germany

Poland

Hong Kong

Spain

Estonia Finland Hong Kong Ireland United Kingdom

Tunisia

United Kingdom

Brazil

Tunisia

South Africa

South Africa

Spain

United States

Fluticasone is also found within below combination drugs:

ADVAIR , AERIVIO SPIROMAX , AERONID , AIRDUO , AIREXAR SPIROMAX , AIRFLUSAL , AIRSUS , ALIFLUS , ALOFLUTE , ANASMA , ASARIS , ATMADISC , AURODISC , AZECORT , BILENI , BISKUS , BRONX AIRMASTER , BROPAIR SPIROMAX , CASOROL CASOMETER , COMBISAL , COMBIWAVE , COMBOTEROL , CYVAX , DUEXON , DYLASTINE , DYMISTA , DYVISTANIL , EVERIO AIRMASTER , FIXKOH AIRMASTER , FLAMERIO , FLIXODIL COMBO , FLUCOSEC , FLUSAMER , FLUSAMIX , FLUSARION , FLUTICOMB , FLUTIFORM , FLUXAL , FOXAIR , FUSACOMB EASYHALER , FUSAMIX EASYHALER , INALADUO , INHALOK FORSPIRO , LIFSAR PULMOJET , LUGANO , NEUAIR AIRMASTER , PAVTIDE , PEIOTAL , PLUSVENT , REXAIR , ROLENIUM , SAFLUTIN , SALFLUMIX EASYHALER , SALFLUTIN , SALFULER , SALMECOMP , SALMESON , SALMEX , SALPLUSF , SAMETEC AIRMASTER , SAMTORAL , SEFFALAIR SPIROMAX , SEREFLO , SERETIDE , SERKEP , SEROFLO , SERROFLO , SIRDUPLA , STALPEX , SYCARA , SYMFLUSAL , SYNAZE , VERIFLO , VIANI , WIXELA INHUB , ZOREEDA

Product monographs

Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
Structured Product Labeling (SPL/PLR)
US
Summary of Product Characteristics (SPC)
Summary of Product Characteristics (SPC)
UK
Structured Product Labeling (SPL/PLR)
US
Structured Product Monograph (SPM)
CA
Summary of Product Characteristics (SPC)
UK

Structural formula

Graphic representation of the active ingredient's molecular structure

Unique ingredient identifier (UNII)

CUT2W21N7U - FLUTICASONE

CAS registry number

80474-14-2 - Fluticasone propionate

90566-53-3 - fluticasone

SNOMED-CT

397192001 - Fluticasone (substance)